Royal Bank of Canada Cuts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $178.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective cut by Royal Bank of Canada from $179.00 to $178.00 in a research report released on Wednesday,Benzinga reports. They currently have an outperform rating on the specialty pharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. TD Cowen decreased their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Needham & Company LLC upped their price target on Jazz Pharmaceuticals from $205.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday. Robert W. Baird upped their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. Finally, Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $182.47.

Jazz Pharmaceuticals Trading Up 0.2 %

Shares of Jazz Pharmaceuticals stock opened at $143.53 on Wednesday. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $148.06. The stock’s 50-day simple moving average is $126.28 and its 200 day simple moving average is $118.79. The stock has a market capitalization of $8.68 billion, a P/E ratio of 20.22, a P/E/G ratio of 1.04 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the transaction, the chief executive officer now directly owns 427,025 shares in the company, valued at $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 5,053 shares of company stock worth $617,442 over the last ninety days. Insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. IFP Advisors Inc bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $25,000. Quadrant Capital Group LLC grew its holdings in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock worth $25,000 after purchasing an additional 101 shares during the last quarter. Elequin Capital LP grew its holdings in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 183 shares during the last quarter. CoreFirst Bank & Trust bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $28,000. Finally, Allianz SE bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $29,000. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.